Kallikrein 7 antibody (AA 30-238)
Quick Overview for Kallikrein 7 antibody (AA 30-238) (ABIN7873578)
Target
See all Kallikrein 7 (KLK7) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 30-238
-
Purpose
- Kallikrein 7 Antibody / Klk7
-
Purification
- Antigen affinity purified
-
Immunogen
- An E.coli-derived rat recombinant protein (K30-N238) was used as the immunogen for the Kallikrein 7 antibody.
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal dilution of the Kallikrein 7 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- After reconstitution, the Kallikrein 7 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- Kallikrein 7 (KLK7)
-
Alternative Name
- Kallikrein 7
-
Background
- Kallikrein-related peptidase 7 (KLK7) is a serine protease that in humans is encoded by the KLK7 gene. KLK7 is a chymotrypsin-like serine protease of the member of peptidase S1 family. It is synthesized with a signal peptide of 22 amino acids (aa 1-22) and a propeptide region (aa 23-29) that are subsequently cleaved to generate the mature form. Human KLK7 displays about 40 to 60 % amino acid homology with other members of the family. It cleaves proteins with aromatic side chains in the P1 position. KLK7 is abundantly expressed in the skin and is also present in the brain, mammary gland, cerebellum, spinal cord, and kidney. Lower levels of expression have been reported in in salivary glands, uterus, thymus, thyroid, placenta, trachea, and testis. Its levels are shown to be up-regulated in ovarian carcinoma, especially late-stage serous carcinoma. Less differentiated tumors of more advanced stage show higher level KLK7 expression. KLK7 activity is inhibited by zinc and copper ions
-
UniProt
- P36373
-
Pathways
- Complement System
Target
-